Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price ...

On Friday, Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $27.98 which represents a slight increase of $0.72 or 2.64% from the prior close of $27.26. The stock opened ...

Stifel Nicolaus analyst Annabel Samimy has maintained their bullish stance on APLS stock, giving a Buy rating today. Annabel Samimy’s ...

Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on APLS stock, giving a Hold rating on November 4. Graig ...

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of -43.75% and 1.04%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the ...

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss ... The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Short interest in Apellis Pharmaceuticals Inc (NASDAQ:APLS) increased during the last ... on the decline of Apellis Pharmaceuticals's stock. Short interest data is updated every two weeks.